InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,246.68
(
0.48%
)
US TECH 100
17,845.20
(
0.69%
)
Dow Jones
39,558.11
(
0.32%
)
Brent Oil
82.66
(
0.13%
)
Bitcoin
61,947.63
(
0.65%
)
Post# of 251821
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119634
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: willyw post# 185020

Monday, 12/22/2014 1:13:51 PM

Monday, December 22, 2014 1:13:51 PM

Post# of 251821
GT4 prevalence in the US is de minimis; in Europe, on the other hand, GT4 is a significant market, which is why Viekira Pak will be approved by the EMA as two products rather than one. I.e., EU patients with GT4 will be able to omit Exviera (ABT-333).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up